Nazma Ilahibaks
@nazmailahibaks
Followers
55
Following
14
Statuses
62
Business Developer | PhD - Sharing ideas on science-based business
Amsterdam, Nederland
Joined October 2019
Are you interested in extracellular vesicles and CRISPR gene editing? Check out the post-doc position on EV-mediated CRISPR delivery for treating a rare cardiomyopathy @UMCUtrecht Don’t miss your chance to apply by January 12th! @ISEV_Journals @NLSEV_
0
2
1
Exciting news! Our latest study published in @ISEV_JEV explores Extracellular Vesicles (EVs) as therapeutic delivery vehicle. We have demonstrated EV-mediated delivery of CRISPR/Cas9 RNP targeting of the Pcsk9 gene ex vivo in primary mouse hepatocytes
0
1
5
"Blijf kritisch en gebruik je boerenverstand." ChatGPT, transformeert ons werk. Gemak ja, maar perfectie? Niet altijd. Lees het volledig artikel in @nrc
0
0
0
TOPX Network in a nutshell: empowering ambitieus women in Life Sciences. Great to reconnect again at the ACE-TOPX event. @TOPXNetwork
0
0
1
FedEx for your cells The potential of extracellular vesicles (tiny bubble-like packages) as a biological delivery service. These vesicles could be the key to treating diseases, from transmitting information between cells to delivering gene therapies.
0
0
1
RT @ISEV_Journals: 👏Read in #JExBio👏@nazmailahibaks et al. examined tissue distribution of #EVs using near-infrared fluorescent imaging. Th…
0
5
0
Studying EV biodistribution and functional delivery simultaneously. Our latest paper ‘Extracellular vesicle-mediated protein delivery to the liver’ published in the @ISEV_Journals J Ex Bio is out.
0
0
5
In the world of biotech, as IPO windows narrow, the landscape shifts. Adaptation is the essence of survival.
0
0
0
EV News: The EMA approved the first MSC-derived EVs interventional study for a Phase 1/2 trial. This trial will assess the safety and efficacy of intratracheal administration of EXOB-001 in preventing Bronchopulmonary Dysplasia (BPD) in preterm newborns.
0
0
2
RT @JamesClear: You do not rise to the level of your goals. You fall to the level of your systems.
0
1K
0
Innovative platform technologies can transform therapeutics, leading to a 9-figure acquisition Lonza has boosted its antibody-drug conjugates ADC offering with the acquisition of Dutch biotechnology company Synaffix for a total consideration of $172m
0
0
1
A new blue print for human DNA. ‘Small’ steps in science, huge leap forward for advanced genome editing opportunities.
0
0
0
Money is the opposite of the weather. Nobody talks about it but everybody does something about it It was great to moderate the @TOPXNetwork event ‘Money & Finance’ @EY last week.
0
0
0
Let's talk about money @TOPXNetwork members can attend for free! Secure your spot today by registering at:
0
0
0
" REPO4EU’s goal is to host and grow a EU industry-level online platform for validated precision drug repurposing with a global reach... a data hub for key information, training resources, matchmaking and collaboration in drug repurposing."
0
0
0
Drug repurposing. Unlock the potential of existing drugs by exploring novel applications, while enhancing precision to revolutionize the drug development process, saving both time and resources. EU-funded platform for repurposing initiatives:
0
0
1
Loading mRNA inside EVs by exposing the donor cells to cellular nanoporation. Interesting loading method
Extracellular vesicles encapsulating mRNA encoding for extracellular-matrix collagen and delivered intradermally via microneedles led to the replacement of collagen in the dermis of mice with photoaged skin.
0
0
0
...Why reproducibility matters as it would have saved Novartis $150 million
0
0
0
One-time base edit to treat one of the most common genetic diseases in infants, affecting~ 1 in 10,000 births
Today we report in @ScienceMagazine a one-time base editing treatment for Spinal Muscular Atrophy (SMA), the leading genetic cause of infant mortality worldwide, affecting ~1 in 10,000 births. PDF: 1/17
0
0
0